Cooper-Standard Holdings CPS 深 沪
已收盘 10-17 16:00:00 美东时间
31.75
-0.770
-2.37%
华盛通- 最 高32.47
- 今 开32.17
- 成交量 16.56万股
- 最 低 31.47
- 昨 收 32.52
- 总市值 5.57亿
- 52周最高 40.67
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 10.375
- 委 比 -0.25%
- 总股本 1754.81万
- 历史最高 146.775
- 量 比 1.14
- 振 幅 3.08%
- 历史最低 3.525
- 每 手 1
- 风险率 8.12%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多impact.com首席营收官莫里森：联盟营销助力出海企业迎接挑战
关税冲击下，企业的营销预算就像一个“缩水的池子”，它们会更倾向于把钱投在能带来更高回报，甚至有收益保障的渠道。 文｜钱丽娜 ID | BMR2004 今年以...
10-14 13:48
拓益速递 | 特瑞普利单抗在巴基斯坦正式获批
1. 本材料旨在传递前沿信息，无意向您做任何产品的推广，不作为临床用药指导。 2. 若您想了解具体疾病诊疗信息，请遵从医疗卫生专业人士的意见与指导。 关于特瑞普...
10-11 17:04
CPS Technologies Corp. Announces Pricing of $9.0 Million Public Offering of Common Stock
CPS Technologies Corp. announced the pricing of a public offering of 3 million shares of common stock at $3.00 per share, generating approximately $9 million in gross proceeds. The net proceeds will be used for general corporate purposes, including working capital and debt repayment. Roth Capital Partners is the sole book-running manager. The company also granted the underwriter a 45-day option to purchase up to an additional 450,000 shares. The ...
10-07 12:24
CPS Technologies Reveals Proposed Public Offering of Common Stock; No Size Disclosed
NORTON, Mass., Oct. 06, 2025 (GLOBE NEWSWIRE) -- CPS Technologies Corp. (NASDAQ:CPSH) ("CPS" or the "Company"), today announced that it intends to offer shares of its common stock in an underwritten public offering. CPS
10-07 04:51
CPS Technologies Awarded Contract From DoE's Office Of Nuclear Energy To Develop Impact Limiter For Spent Nuclear Fuel, Radioactive Waste Transport
NORTON, Mass., Sept. 29, 2025 (GLOBE NEWSWIRE) -- CPS Technologies Corp. (NASDAQ: CPSH) ("CPS" or the "Company") today announced it has been awarded a Phase I Small Business Innovation Research (SBIR) contract from the
09-30 04:13
美国政府取消年度饥饿调查
美国农业部（USDA）确认，将取消自上世纪90年代中期以来持续开展的年度食物不安全（food insecurity）调查。这项调查原本每年12月进行，覆盖约...
09-21 14:45
PDS Biotech Reports 29.5-Month Median Overall Survival In Phase 2 Trial For Advanced Head And Neck Cancer; Says Encouraging Efficacy Signal Observed In Difficult To Treat Category Of Advanced Head And Neck Cancer Patients
First combination therapy to report 29.5 months of Median Overall Survival (mOS); Standard of care Keytruda® (pembrolizumab) alone (10.8 months) and Keytruda® + chemotherapy (12.3 months) in patients with CPS
09-18 20:47
ISOENERGY AND PUREPOINT INTERSECT UP TO 8.1% U₃O₈ AT DORADO PROJECT
TORONTO, Sept. 18, 2025 /PRNewswire/ - IsoEnergy Ltd. (NYSE American: ISOU) (TSX: ISO) ("IsoEnergy") and Purepoint Uranium Group Inc. (TSXV: PTU) (OTC: PTUUF) ("Purepoint") today announced t...
09-18 18:30
Cooper-Standard Holdings Extends Section 382 Rights Agreement
Cooper-Standard Holdings ( ($CPS) ) has shared an announcement. On September 12...
09-13 05:02
